Evidence map›Paper›PMID 42582979›Full record

ReviewESMO gastrointestinal oncology2026

Optimising chemoradiotherapy in anal cancer.

P Franco, L Deantonio, R Muirhead, A Gilbert, M A Gambacorta, C Kronborg, M G Guren

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

P FrancoDepartment of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy.
L DeantonioRadiation Oncology Clinic, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
R MuirheadOxford University Hospitals NHS Foundation Trust, Oxford, UK.
A GilbertLeeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
M A GambacortaDepartment of Radiology and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
C KronborgDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
M G GurenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concurrent chemoradiotherapy is the standard treatment for localised squamous-cell carcinoma of the anus. Even though this approach is well established, research efforts are ongoing to optimise this therapeutic option to maximise oncological outcomes, decrease treatment-related toxicity profile, and optimise health-related quality of life. We provide an overview of the available data and the active fields of research in the optimisation of chemoradiotherapy in anal cancer patients.

Indexed as

anal cancerconcurrent chemoradiotherapyhealth-related quality of liferadiotherapy

Identifiers

PMID42582979
PMCPMC13459600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.